Pages that link to "Q36529933"

The following pages link to Targeting epigenetic abnormalities with histone deacetylase inhibitors (Q36529933):

Displaying 12 items.

• uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells (Q30443804) (← links)
• Histone deacetylase regulation of immune gene expression in tumor cells (Q35092304) (← links)
• Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents (Q35603419) (← links)
• Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylation (Q37199052) (← links)
• Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern? (Q37723147) (← links)
• Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells (Q38821693) (← links)
• Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity. (Q38822524) (← links)
• Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation (Q38939048) (← links)
• Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma (Q39136897) (← links)
• Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells (Q39915669) (← links)
• Largazole Analogues Embodying Radical Changes in the Depsipeptide Ring: Development of a More Selective and Highly Potent Analogue (Q47154262) (← links)
• Synthesis of HDAC Substrate Peptidomimetic Inhibitors Using Fmoc Amino Acids Incorporating Zinc-Binding Groups (Q64103438) (← links)